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Background
Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cho-
lesterol levels in patients who are receiving statin therapy. Larger and longer-term 
studies are needed to establish safety and efficacy.
Methods
We conducted a randomized trial involving 2341 patients at high risk for cardiovas-
cular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per 
liter) or more and were receiving treatment with statins at the maximum tolerated 
dose (the highest dose associated with an acceptable side-effect profile), with or without 
other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive 
alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks 
for 78 weeks. The primary efficacy end point was the percentage change in calcu-
lated LDL cholesterol level from baseline to week 24.
Results
At week 24, the difference between the alirocumab and placebo groups in the mean 
percentage change from baseline in calculated LDL cholesterol level was −62 per-
centage points (P<0.001); the treatment effect remained consistent over a period of 
78 weeks. The alirocumab group, as compared with the placebo group, had higher 
rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocog-
nitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post 
hoc analysis, the rate of major adverse cardiovascular events (death from coronary 
heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or 
unstable angina requiring hospitalization) was lower with alirocumab than with 
placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; 
nominal P = 0.02).
Conclusions
Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum 
tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, 
there was evidence of a reduction in the rate of cardiovascular events with alirocumab. 
(Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM 
ClinicalTrials.gov number, NCT01507831.)
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Monoclonal antibodies to propro-tein convertase subtilisin–kexin type 9 (PCSK9) have been shown to reduce 
low-density lipoprotein (LDL) cholesterol levels 
in patients who are being treated with statins. In 
phase 2 studies lasting 8 to 12 weeks, the PCSK9 
inhibitor alirocumab lowered LDL cholesterol 
levels by 40 to 70% when added to background 
statin therapy.1-3 However, this new treatment 
needs to be evaluated in larger populations for 
longer periods of follow-up to establish its safety 
and efficacy.4-7
We conducted a 78-week trial comparing ali-
rocumab (150 mg every 2 weeks) with placebo in 
2341 patients at high risk for cardiovascular 
events who were receiving treatment with statins 
at the maximum tolerated dose (the highest dose 
associated with an acceptable side-effect profile), 
with or without other lipid-lowering therapy. The 
trial, which was entitled Long-term Safety and 
Tolerability of Alirocumab in High Cardiovascu-
lar Risk Patients with Hypercholesterolemia Not 
Adequately Controlled with Their Lipid Modify-
ing Therapy (ODYSSEY LONG TERM), was de-
signed to obtain longer-term data on safety and 
reduction in LDL cholesterol levels. We also 
collected data on prespecified adjudicated car-
diovascular outcomes and performed a post hoc 
analysis of the composite end point of major 
adverse cardiovascular events.
ME THODS
Study Design and Oversight
The ODYSSEY LONG TERM trial was a phase 3, 
randomized, double-blind, placebo-controlled, 
parallel-group, multinational study, which was 
conducted at 320 sites in 27 countries throughout 
Africa, Europe, and North and South America. 
The study was funded by Sanofi and Regeneron 
Pharmaceuticals.
The sponsors and the steering committee de-
signed the trial protocol, which is available with 
the full text of this article at NEJM.org. The pro-
tocol was approved by the institutional review 
board at each participating center. The sponsors 
collected, managed, and analyzed the data under 
the supervision of the steering committee. The 
first draft of the manuscript was prepared by the 
first author and was thereafter critically reviewed 
and revised by all the authors. The sponsors pro-
vided comments on an early draft. Editorial as-
sistance was provided by Prime Medica, funded 
by Sanofi and Regeneron Pharmaceuticals. The 
academic authors had unrestricted access to the 
data and vouch for the accuracy and complete-
ness of the data and all analyses, as well as for 
the fidelity of this report to the trial protocol.
Study Population
Adult patients (≥18 years of age) with heterozy-
gous familial hypercholesterolemia (as determined 
by genotyping or clinical criteria) or with estab-
lished coronary heart disease or a coronary heart 
disease risk equivalent (as defined in Table 1) were 
eligible for inclusion if they had an LDL choles-
terol level of 70 mg per deciliter (1.8 mmol per 
liter) or more at the time of screening. All patients 
were required to be receiving either high-dose 
statin therapy (as defined in Table 1) or statin 
therapy at the maximum tolerated dose, with or 
without other lipid-lowering therapy, for at least 
4 weeks before screening (6 weeks for fenofibrate); 
this lipid-lowering regimen was continued through-
out the study. Full eligibility criteria are listed in 
the Supplementary Appendix, available at NEJM 
.org. All participants provided written informed 
consent.
Study Procedures
After a 3-week screening period, eligible pa-
tients were randomly assigned, in a 2:1 ratio, to 
receive alirocumab (150 mg) or placebo, in a 
double-blind fashion, every 2 weeks for 78 weeks 
(in addition to their statin therapy, with or with-
out other lipid-lowering therapy; see Fig. S1 in 
the Supplementary Appendix). Both alirocumab 
and placebo were administered as a single 1-ml 
subcutaneous injection, which was provided in 
a prefilled syringe. All patients were instructed 
to follow a stable Therapeutic Lifestyle Changes 
diet, as outlined by the Adult Treatment Panel III 
of the National Cholesterol Education Program, 
or an equivalent diet for the duration of the 
study.
Patients were to return to the study site dur-
ing the double-blind study period at weeks 0 (base-
line), 4, 8, 12, 16, 24, 36, 52, 64, and 78, and 
again 8 weeks after the end of the double-blind 
period (i.e., at week 86) for a safety assessment. 
Further details on randomization, assessment of 
adherence and exposure to the study drug, and 
laboratory assessments are provided in the Sup-
plementary Appendix.
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Table 1. Baseline Characteristics of All Randomly Assigned Patients.*
Characteristic
Alirocumab  
(N = 1553)
Placebo  
(N = 788)
Demographic variables
Age — yr 60.4±10.4 60.6±10.4
Male sex — no. (%) 983 (63.3) 474 (60.2)
White race — no. (%)† 1441 (92.8) 730 (92.6)
Cardiovascular history and risk factors
Body-mass index‡ 30.2±5.7 30.5±5.5
Heterozygous familial hypercholesterolemia — no. (%)§ 276 (17.8) 139 (17.6)
Coronary heart disease — no. (%) 1055 (67.9) 552 (70.1)
Coronary heart disease risk equivalent — no. (%)¶ 639 (41.1) 323 (41.0)
Type 2 diabetes — no. (%) 542 (34.9) 267 (33.9)
Current smoker — no. (%) 325 (20.9) 159 (20.2)
Lipid-modifying medications — no. (%)
Any statin 1552 (>99.9) 787 (99.9)
High-dose statin‖ 727 (46.8) 368 (46.7)
Other lipid-lowering therapy 437 (28.1) 220 (27.9)
Ezetimibe 216 (13.9) 118 (15.0)
Lipid and lipoprotein levels — mg/dl
Calculated LDL cholesterol**
Mean 122.7±42.6 121.9±41.4
Range 39–424 19–404
Non-HDL cholesterol 152.6±46.6 152.0±45.8
Apolipoprotein B 101.9±27.7 101.4±27.3
Lipoprotein(a)
Median 22.2 20.9
Interquartile range 7.6–66.5 6.5–66.8
Fasting triglycerides
Median 132.0 135.0
Interquartile range 93.8–183.2 94.7–188.5
HDL cholesterol 49.8±12.2 50.0±12.4
Apolipoprotein A1 146.5±25.1 147.3±27.3
* Plus–minus values are means ±SD. The P value for all between-group comparisons was greater than 0.05, indicating 
no significant differences. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert 
the values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, and LDL 
low-density lipoprotein.
† Race was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Heterozygous familial hypercholesterolemia was diagnosed by means of genotyping in 40.2% of the patients in the 
two groups combined and by clinical criteria (World Health Organization–Simon Broome diagnostic criteria) in 59.8% 
of the patients in the two groups combined.
¶ Coronary heart disease risk equivalents were defined as peripheral arterial disease, ischemic stroke, moderate chronic 
kidney disease (estimated glomerular filtration rate, 30 to <60 ml per minute per 1.73 m2 of body-surface area), or di-
abetes mellitus plus two or more additional risk factors (hypertension; ankle–brachial index of ≤0.90; microalbumin-
uria, macroalbuminuria, or a urinary dipstick result of >2+ protein; preproliferative or proliferative retinopathy or laser 
treatment for retinopathy; or a family history of premature coronary heart disease).
‖ High-dose statin therapy was defined as a daily dose of 40 to 80 mg of atorvastatin, 20 to 40 mg of rosuvastatin, or 
80 mg of simvastatin.
** LDL cholesterol levels were calculated with the use of the Friedewald formula and also measured by means of beta-
quantification (see Table S1 in the Supplementary Appendix).
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End Points
The primary efficacy end point was the percent-
age change in calculated LDL cholesterol level 
from baseline to week 24, analyzed with the use 
of an intention-to-treat approach. Secondary end 
points included the percentage change in LDL 
cholesterol level while the study drug was being 
taken, as well as other lipoprotein variables at 
weeks 12 and 24 in both the intention-to-treat 
analysis and the analysis that included only pa-
tients who were receiving the study drug. All the 
efficacy end points are listed in the Supplemen-
tary Appendix.
Safety end points were adverse events, includ-
ing symptoms, laboratory abnormalities, vital-sign 
abnormalities, electrocardiographic abnormali-
ties, and adjudicated cardiovascular events, that 
occurred after the first injection and up to 10 
weeks after the last injection. Adverse events are 
reported as the number of patients having an 
event in each category, classified according to the 
Medical Dictionary for Regulatory Activities (MedDRA). 
The safety of patients with an LDL cholesterol 
level of less than 25 mg per deciliter (0.6 mmol 
per liter) at two consecutive measurements was 
specifically monitored by a dedicated member of 
the data and safety monitoring committee and 
an independent physician (see the Supplementary 
Appendix for details).
We performed a post hoc analysis that com-
pared the rate of positively adjudicated major ad-
verse cardiovascular events between the two study 
groups, using the composite end point of death 
from coronary heart disease, nonfatal myocardial 
infarction, fatal or nonfatal ischemic stroke, or 
unstable angina requiring hospitalization. This 
composite end point was selected because it is 
the primary end point of the ongoing Study to 
Evaluate the Effect of Alirocumab on the Occur-
rence of Cardiovascular Events in Patients Who 
Have Experienced an Acute Coronary Syndrome 
(ODYSSEY OUTCOMES).8 The prespecified defi-
nitions of cardiovascular events are provided in 
the Supplementary Appendix.
Statistical Analysis
For the safety assessment, we estimated that a 
sample of 2100 patients (1400 patients treated 
with alirocumab and 700 with placebo) would in-
clude at least 1000 patients exposed to alirocumab 
for a minimum of 12 months and approximately 
900 patients exposed to alirocumab for 18 months 
at the study end (assuming dropout rates of 25% 
and 35% at 12 and 18 months, respectively). This 
sample size would allow detection of adverse events 
with a rate of 0.2% or more in the alirocumab 
group with 95% confidence.
The intention-to-treat analysis that was used 
for the evaluation of the primary end point in-
cluded all LDL cholesterol values that were col-
lected, regardless of whether they were obtained 
while the patient was receiving the study drug or 
after the study drug was discontinued, up to 
week 24. We accounted for missing data by us-
ing a mixed-effects model for repeated mea-
sures. Patients who discontinued the study drug 
prematurely were asked to return for further 
clinic visits and assessments until the sched-
uled final visit.
The assessment of continuous secondary ef-
ficacy end points was similar to the assessment 
of the primary efficacy end point, except in the 
case of the end points of lipoprotein(a) and tri-
glyceride levels (which were analyzed with the 
use of multiple imputation, followed by robust 
regression), and the end point of reaching LDL 
cholesterol goals (which was analyzed with the 
use of multiple imputation, followed by logistic 
regression). A Cox proportional-hazards model 
was used in the post hoc analysis to compare 
rates of major adverse cardiovascular events be-
tween the two study groups.
The safety population included all randomly 
assigned patients who received at least one dose 
or part of a dose of a study drug. Safety data were 
analyzed descriptively.
R ESULT S
Patient Characteristics and Follow-up
A total of 2341 patients were enrolled in the 
trial, of whom 1553 were assigned to alirocumab 
and 788 to placebo (Fig. 1). Demographic char-
acteristics and clinical history were well bal-
anced between the two study groups (Table 1). 
The mean age of the study participants was 60 
years, and 37.8% were women. A total of 68.9% 
of the patients had a history of coronary heart 
disease, and 17.7% had heterozygous familial hy-
percholesterolemia. All but 2 patients overall 
were receiving a statin, and 46.8% of the patients 
were receiving high-dose statin therapy; 28.1% 
were also receiving other lipid-lowering therapy. 
The mean calculated LDL cholesterol level at 
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baseline was 122 mg per deciliter (3.2 mmol per 
liter).
The mean study-drug exposure among the 
2338 patients included in the safety analysis 
(1550 in the alirocumab group and 788 in the 
placebo group) was 70 weeks (Fig. 1), providing 
2061 patient-years of exposure to alirocumab at 
a dose of 150 mg every 2 weeks. The mean rate 
of adherence to the study drug (i.e., the percent-
age of days that patients received their injections 
as per the planned dosing schedule) was 98.0% 
and 97.6% in the alirocumab group and the pla-
cebo group, respectively. The mean duration of 
follow-up (regardless of adherence to the study 
drug) in the safety population was 80.9 weeks in 
the alirocumab group and 80.1 weeks in the 
placebo group.
The rate of study-drug discontinuation was 
28.2% in the alirocumab group and 24.5% in the 
placebo group. A total of 98.7% of the patients 
met the criteria for the intention-to-treat popula-
tion and thus were included in the primary effi-
cacy analysis. At week 24, a total of 144 patients 
(9.4%) in the alirocumab group and 72 patients 
(9.2%) in the placebo group had missing LDL 
cholesterol values (Table S1 in the Supplementary 
Appendix). These missing values were accounted 
for with the use of the mixed-effects model for 
repeated measures.
Efficacy
The mean percentage change in calculated LDL 
cholesterol level from baseline to week 24 was 
−61.0% with alirocumab versus 0.8% with pla-
cebo, for a difference of −61.9 percentage points 
(P<0.001) (Table 2 and Fig. 2). The mean abso-
lute LDL cholesterol level at week 24 was 48 mg 
per deciliter (1.2 mmol per liter) in the alirocumab 
group and 119 mg per deciliter (3.1 mmol per 
liter) in the placebo group, corresponding to a 
mean absolute change from baseline of −74 mg 
per deciliter (−1.9 mmol per liter) and −4 mg per 
deciliter (−0.1 mmol per liter), respectively. The 
goal of an LDL cholesterol level of less than 70 mg 
per deciliter at week 24 was met by 79.3% of the 
patients in the alirocumab group versus 8.0% of 
the patients in the placebo group (P<0.001). A 
consistent reduction in LDL cholesterol level 
from baseline was observed from week 4 to 
week 78 in the alirocumab group (Fig. 2). Re-
sults of measured LDL cholesterol levels were 
consistent with those of calculated LDL choles-
terol levels (Table S2 in the Supplementary Ap-
pendix).
The percentage decrease in LDL cholesterol 
level in the alirocumab group was slightly lower 
at week 78 (52.4%) than at week 24 (61.0%) in 
the intention-to-treat analysis (Table 2); this ob-
servation was influenced by levels obtained after 
premature discontinuation of treatment. The 
58.0% reduction in LDL cholesterol level at week 
78 in the analysis that included only patients 
2341 Underwent randomization
5142 Patients were assessed
for eligibility
2801 Were excluded
2799 Did not meet study criteria
2 Received study drug but did
not undergo randomization
1553 Were assigned to alirocumab
1550 Received alirocumab
3 Did not receive alirocumab
788 Were assigned to placebo
788 Received placebo
595 Completed study
193 Did not complete study
47 Had adverse events
38 Were nonadherent
108 Had other reasons
1113 Completed study
437 Did not complete study
113 Had adverse events
60 Were nonadherent
264 Had other reasons
788 Were included in the safety analysis
780 Were included in the intention-to-
treat analysis
8 Were excluded owing to no
LDL cholesterol value during 
one of the analysis windows
up to wk 24
708 Had LDL cholesterol value at wk 24
1550 Were included in the safety analysis
1530 Were included in the intention-to-
treat analysis
23 Were excluded owing to no
LDL cholesterol value during
one of the analysis windows
up to wk 24
1386 Had LDL cholesterol value at wk 24
Figure 1. Randomization and Treatment.
The intention-to-treat population included all randomly assigned patients 
who had both a baseline calculated low-density lipoprotein (LDL) choles-
terol value and at least one calculated LDL cholesterol value during one of 
the analysis windows up to week 24. The three patients in the alirocumab 
group who underwent randomization but did not receive treatment are in-
cluded in the intention-to-treat population. Completion of the study was 
defined, as per the electronic case-report form, in the following way: the 
last study-drug injection was received (week 76), and the end-of-treatment 
visit (week 78) occurred within 21 days after the last injection and at least 
525 days after randomization.
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who were receiving the study drug was more 
consistent with the 62.8% reduction at week 24 
(Table S3 in the Supplementary Appendix). Anal-
ysis of the primary end point with the use of a 
pattern-mixture model yielded results that were 
similar to those of the analysis in which a 
mixed-effects model for repeated measures was 
used (Table S4 in the Supplementary Appendix).
The difference between the alirocumab and 
placebo groups in the percentage change in LDL 
cholesterol level from baseline to week 24 was 
similar in patients with heterozygous familial 
Table 2. Primary Efficacy End Point and Selected Secondary Efficacy End Points in the Intention-to-Treat Population.*
End Point
Alirocumab 
(N = 1530)
Placebo 
(N = 780) Alirocumab vs. Placebo
Least-Squares 
Mean 
Difference 95% CI P Value
Primary efficacy end point: calculated LDL cholesterol
Baseline level — mg/dl
Mean† 122.8±42.7 122.0±41.6
Range 39–424 19–404
Absolute level at wk 24 — mg/dl 48.3±0.9 118.9±1.2
Absolute change from baseline to wk 24 — mg/dl −74.2±0.9 −3.6±1.2
Percentage change from baseline to wk 24 −61.0±0.7 0.8±1.0 −61.9±1.3 −64.3 to –59.4 <0.001
Selected secondary efficacy end points
Proportion of patients who reached prespecified calculated 
LDL cholesterol levels by wk 24 — %‡
<70 mg/dl in patients at very high risk or <100 mg/dl in  
patients at high risk
80.7 8.5 <0.001
<70 mg/dl regardless of risk 79.3 8.0 <0.001
Percentage change from baseline to wk 78 in calculated LDL 
cholesterol
−52.4±0.9 3.6±1.3 −56.0±1.6 −59.1 to −52.8 <0.001§
Percentage change from baseline to wk 24 in secondary  
lipid variables
Non-HDL cholesterol −51.6±0.6 0.7±0.9 −52.3±1.1 −54.4 to −50.2 <0.001
Apolipoprotein B −52.8±0.7 1.2±1.0 −54.0±1.2 −56.3 to −51.7 <0.001
Total cholesterol −37.8±0.5 −0.3±0.7 −37.5±0.8 −39.1 to −35.9 <0.001
Lipoprotein(a)¶ −29.3±0.7 −3.7±1.0 −25.6±1.3 −28.1 to −23.1 <0.001
Fasting triglycerides¶ −15.6±0.8 1.8±1.2 −17.3±1.4 −20.1 to −14.6 <0.001
HDL cholesterol 4.0±0.4 −0.6±0.5 4.6±0.7 3.3 to 5.9 <0.001
Apolipoprotein A1 4.0±0.4 1.2±0.6 2.9±0.7 1.6 to 4.2 <0.001
* Plus–minus values are least-squares means ±SE, unless otherwise indicated. Primary and secondary efficacy analyses were performed with 
the use of an intention-to-treat approach, which included patients with a baseline calculated LDL cholesterol value and at least one calculat-
ed LDL cholesterol value during or after receipt of the study drug within one of the analysis windows up to week 24. A prespecified analysis 
that included only patients who were receiving the study drug was also performed (Table S3 in the Supplementary Appendix). Least-squares 
means (±SE) and P values were calculated with the use of a mixed-effects model with repeated-measures analysis (except for end points 
noted in the footnotes below). The P values are significant according to the fixed hierarchical approach used to ensure control of the overall 
type I error rate at the 0.05 level. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. CI denotes confidence in- 
terval.
† Plus–minus values are means ±SD.
‡ The analysis of this end point was performed with the use of multiple imputation, followed by logistic regression. The combined estimate of 
the proportion of patients was obtained by calculation of the average of all the imputed proportions of patients meeting the level of interest.
§ The P value has not been adjusted for multiple testing and is provided for descriptive purposes only.
¶ The percentage change in levels of lipoprotein(a) and triglycerides was analyzed with the use of multiple imputation, followed by robust re-
gression. A combined estimate for adjusted mean (±SE) is shown.
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hypercholesterolemia and those without it (Fig. 
S2A in the Supplementary Appendix). Across four 
subgroups defined according to baseline LDL cho-
lesterol level, alirocumab reduced the LDL choles-
terol level by 59.5 to 62.0%; the difference be-
tween the alirocumab and placebo groups in the 
percentage change from baseline to week 24 was 
smaller among patients who had higher LDL cho-
lesterol levels at baseline (Fig. S2B in the Supple-
mentary Appendix). The between-group differ-
ence in the percentage change in LDL cholesterol 
level from baseline to week 24 was greater among 
those with PSCK9 levels at or above the median 
than among those with levels below the median, 
with this finding driven mostly by larger within-
group differences observed in the placebo group 
(Fig. S3A in the Supplementary Appendix). Mild 
heterogeneity of treatment effect was observed 
for some other subgroup characteristics such as 
sex (Fig. S3B in the Supplementary Appendix) 
and geographic region (Fig. S4 in the Supple-
mentary Appendix). Nonetheless, an additional 
reduction in LDL cholesterol level of approxi-
mately 50 to 65 percentage points was observed 
across various subgroups defined by demograph-
ic and baseline characteristics including race, age, 
presence or absence of diabetes status, and back-
ground statin therapy (Fig. S4 in the Supplemen-
tary Appendix).
Results for other lipid variables are shown in 
Table 2. As compared with the placebo group, 
the alirocumab group had greater reductions 
from baseline to week 24 in levels of non–high-
density lipoprotein (HDL) cholesterol (differ-
ence [alirocumab minus placebo], −52.3 per-
centage points), apolipoprotein B (difference, 
−54.0 percentage points), total cholesterol (dif-
ference, −37.5 percentage points), lipoprotein(a) 
(difference, −25.6 percentage points), and triglyc-
erides (difference, −17.3 percentage points) and 
had a modest increase in levels of HDL choles-
terol (difference, 4.6 percentage points) and apo-
lipoprotein A1 (difference, 2.9 percentage points) 
(P<0.001 for all comparisons).
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Figure 2. Calculated LDL Cholesterol Levels over Time (Intention-to-Treat Analysis).
Calculated LDL cholesterol levels are shown in milligrams per deciliter (left axis) and millimoles per liter (right axis). 
Values above the data points indicate least-squares mean absolute LDL cholesterol levels, and values below the data 
points indicate least-squares mean percentage changes from baseline. Values below the chart indicate the number 
of patients with LDL cholesterol values available for the intention-to-treat analysis at each time point; these include 
levels measured while the study drug was being taken and, in the case of patients who discontinued the study drug 
but returned to the clinic for assessments, after the study drug was discontinued. Missing data were accounted for 
with the use of a mixed-effects model with repeated measures. For statin therapy, the maximum tolerated dose was 
the highest dose associated with an acceptable side-effect profile. LLT denotes lipid-lowering therapy.
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Safety
The percentage of patients with any adverse event 
was similar in the two study groups (81.0% with 
alirocumab and 82.5% with placebo) (Table 3). 
Adverse events leading to study-drug discontinu-
ation occurred in 7.2% of the patients who re-
ceived alirocumab and 5.8% of the patients who 
received placebo. With regard to specific adverse 
events, the alirocumab group had higher rates 
than the placebo group of injection-site reactions 
(5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neuro-
cognitive events (1.2% vs. 0.5%), and ophthalmo-
logic events (2.9% vs. 1.9%) (Table 3, and Table 
S5 in the Supplementary Appendix). Neurocogni-
tive events included amnesia, memory impair-
ment, and confusional state (Table 3, and Table 
S6 in the Supplementary Appendix). No cases of 
hemolytic anemia were reported. Rare and some-
times serious cases of neurologic and general al-
lergic events were reported in both study groups 
(Table S7 in the Supplementary Appendix).
Among patients without a medical history of 
diabetes at baseline, 1.8% of the patients who 
received alirocumab and 2.0% of the patients who 
received placebo had at least one adverse event 
identified by the custom MedDRA query “diabe-
tes” (which identified a set of adverse events 
selected by the study sponsors as being related 
Table 3. Adverse Events of Interest and Laboratory Values: Safety Analysis.*
Event
Alirocumab 
(N = 1550)
Placebo 
(N = 788) P Value†
Summary of adverse events — no. of patients (%)
Any adverse event 1255 (81.0) 650 (82.5) 0.40
Serious adverse event 290 (18.7) 154 (19.5) 0.66
Adverse event leading to study-drug discontinuation 111 (7.2) 46 (5.8) 0.26
Adverse event leading to death 8 (0.5) 10 (1.3) 0.08
Cardiovascular adverse events of interest — no. of patients (%)
Death from coronary heart disease, including death from unknown cause 4 (0.3) 7 (0.9) 0.26
Nonfatal myocardial infarction 14 (0.9) 18 (2.3) 0.01
Fatal or nonfatal ischemic stroke 9 (0.6) 2 (0.3) 0.35
Unstable angina requiring hospitalization 0 1 (0.1) 0.34
Congestive heart failure requiring hospitalization 9 (0.6) 3 (0.4) 0.76
Ischemia-driven coronary revascularization procedure 48 (3.1) 24 (3.0) 1
Positively adjudicated cardiovascular events, including all cardiovascular adverse 
events listed above
72 (4.6) 40 (5.1) 0.68
Adjudicated major adverse cardiovascular events in post hoc analysis‡ 27 (1.7) 26 (3.3) 0.02
Other adverse events of interest
General allergic reaction — no. of patients (%) 156 (10.1) 75 (9.5) 0.71
Local injection-site reaction — no. of patients (%) 91 (5.9) 33 (4.2) 0.10
Myalgia — no. of patients (%) 84 (5.4) 23 (2.9) 0.006
Neurologic event — no. of patients (%)§ 65 (4.2) 35 (4.4) 0.83
Neurocognitive disorder — no. of patients (%)¶ 18 (1.2) 4 (0.5) 0.17
Amnesia 5 (0.3) 0 0.17
Memory impairment 4 (0.3) 1 (0.1) 0.67
Confusional state 4 (0.3) 1 (0.1) 0.67
Ophthalmologic event — no. of patients (%)‖ 45 (2.9) 15 (1.9) 0.65
Hemolytic anemia — no. of patients 0 0 NC
Diabetes in patients with no history of diabetes — no. of patients/total no. (%)** 18/994 (1.8) 10/509 (2.0) 0.84
Worsening of diabetes in patients with history of diabetes — no. of patients/total  
no. (%)**
72/556 (12.9) 38/279 (13.6) 0.83
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to newly diagnosed diabetes or worsening of 
preexisting diabetes; see the Supplementary Ap-
pendix) (Table 3). Abnormal levels of amino-
transferases or creatine kinase were uncommon 
and occurred at similar rates in the two study 
groups (Table 3).
Among the patients who received alirocumab, 
575 (37.1%) had a calculated LDL cholesterol 
level of less than 25 mg per deciliter at two con-
secutive measurements. Rates of adverse events 
among these patients were similar to those among 
the overall alirocumab group (Table S5 in the 
Supplementary Appendix). A greater number of 
patients in the alirocumab group than in the pla-
cebo group had a level of vitamin E or vitamin K 
that was below the lower limit of the normal range 
after baseline; however, there were no clinically 
meaningful changes. No clinically meaningful ef-
fect was observed with respect to changes in levels 
of other fat-soluble vitamins or cortisol (Table S8 
in the Supplementary Appendix).
Cardiovascular Events
Positively adjudicated cardiovascular adverse events 
occurred in 4.6% of the patients in the alirocumab 
group and in 5.1% of the patients in the placebo 
group (Table 3). In a post hoc analysis that evalu-
ated the prespecified primary end point in the 
ongoing ODYSSEY OUTCOMES trial (major ad-
verse cardiovascular events: a composite of death 
from coronary heart disease, nonfatal myocardial 
infarction, fatal or nonfatal ischemic stroke, or un-
stable angina requiring hospitalization), a lower 
rate of adjudicated major adverse cardiovascular 
events was observed in the alirocumab group 
(27 of 1550 patients [1.7%]) than in the placebo 
group (26 of 788 patients [3.3%]; hazard ratio, 
0.52; 95% confidence interval, 0.31 to 0.90; 
nominal P = 0.02) (Table 3). The cumulative inci-
dence curves diverged progressively over time 
(Fig. S5 in the Supplementary Appendix).
DISCUSSION
In the ODYSSEY LONG TERM trial, the PCSK9 
inhibitor alirocumab, as compared with placebo, 
reduced LDL cholesterol levels by an additional 
62 percentage points in high-risk patients when 
added to statin therapy at the maximum tolerated 
dose, with or without other lipid-lowering thera-
Table 3. (Continued.)
Event
Alirocumab 
(N = 1550)
Placebo 
(N = 788) P Value†
Laboratory values of interest — no. of patients/total no. (%)
Alanine aminotransferase >3× ULN 28/1533 (1.8) 16/779 (2.1) 0.75
Aspartate aminotransferase >3× ULN 22/1533 (1.4) 18/779 (2.3) 0.13
Creatine kinase >3× ULN 56/1507 (3.7) 38/771 (4.9) 0.18
* Adverse events were defined as those that developed, worsened, or became serious after the first injection and up to 10 weeks after the 
last injection. NC denotes not calculated, and ULN upper limit of the normal range.
† P values were calculated with the use of Fisher’s exact test and have not been adjusted for multiple testing. They are provided for descrip-
tive purposes only.
‡ The post hoc analysis was not specified in the study protocol. It included the following cardiovascular event categories, which also com-
prise the end point in the Study to Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have 
Experienced an Acute Coronary Syndrome (ODYSSEY OUTCOMES): death from coronary heart disease, nonfatal myocardial infarction, fa-
tal or nonfatal ischemic stroke, and unstable angina requiring hospitalization.8 “Unstable angina requiring hospitalization” is limited to 
the unstable angina events with definite evidence of progression of the ischemic condition (strict criteria). Congestive heart failure requir-
ing hospitalization and ischemia-driven coronary revascularization procedure were not included in the post hoc analysis.
§ The selection of preferred terms is based on a standardized Medical Dictionary for Regulatory Activities (MedDRA) query including “demye-
lination” (broad and narrow terms), “peripheral neuropathy” (broad and narrow terms), and “Guillain–Barré syndrome” (broad and nar-
row terms), excluding the preferred terms “acute respiratory distress syndrome,” “asthenia,” “respiratory arrest,” and “respiratory failure.”
¶ Neurocognitive events were selected with the use of a custom MedDRA query that was based on the following five High-Level Group 
Terms: “deliria (including confusion),” “cognitive and attention disorders and disturbances,” “dementia and amnestic conditions,” “dis-
turbances in thinking and perception,” and “mental impairment disorders.” See also Table S6 in the Supplementary Appendix.
‖ The selection of preferred terms is based on a standardized MedDRA query that included “optic nerve disorders” (broad and narrow 
terms), “retinal disorders” (narrow term), and “corneal disorders” (narrow term).
** The selection of preferred terms is based on the custom MedDRA query “diabetes,” which includes the High-Level Group Term “diabetes 
complications,” the High-Level Term “diabetes mellitus,” and the High-Level Term “carbohydrate tolerance analyses (including diabetes)” 
(excluding the preferred terms “blood glucose decreased” and “hyperglycemia”). A full list of preferred terms is provided in the 
Supplementary Appendix.
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py. The effect was consistent over a period of 78 
weeks of therapy. The efficacy of alirocumab was 
similar across various subgroups, including those 
defined according to the presence or absence of 
heterozygous familial hypercholesterolemia. There 
was a reduction of 26 percentage points versus 
placebo in levels of lipoprotein(a), a finding con-
sistent with that of phase 2 trials.9 Our findings 
are similar to those of randomized placebo-con-
trolled or open-label studies of another PCSK9 
inhibitor, in which the LDL cholesterol levels de-
creased by 52 to 57%.10,11
Adverse events that occurred more frequently 
with alirocumab than with placebo included 
injection-site reactions, myalgia, neurocognitive 
disorders, and ophthalmologic disorders. Neuro-
cognitive disorders were related primarily to 
memory. The rare neurologic serious adverse 
events observed with alirocumab have distinct 
immunologic or inflammatory causes, so it seems 
unlikely that they share a common cause such as 
alirocumab treatment or low LDL cholesterol 
level. Allergic adverse events observed in the 
alirocumab group may be related to alirocumab 
treatment, because allergic reactions have been 
associated with the use of other monoclonal 
antibodies. Alirocumab had no untoward effect 
with respect to the development or exacerbation 
of diabetes or with respect to levels of amino-
transferases or creatine kinase. The frequency of 
adverse events was similar among patients who 
had an LDL cholesterol level of less than 25 mg 
per deciliter at two consecutive measurements 
and those who did not.
In a post hoc safety analysis, the rate of major 
adverse cardiovascular events (a composite end 
point of death from coronary heart disease, non-
fatal myocardial infarction, fatal or nonfatal 
ischemic stroke, or unstable angina requiring 
hospitalization) was 48% lower among patients 
who received alirocumab than among those who 
received placebo during the 80 weeks of follow-
up (nominal P = 0.02). When all adjudicated 
cardiovascular events were included (i.e., with 
the addition of congestive heart failure requir-
ing hospitalization and ischemia-driven coro-
nary revascularization), the difference between 
groups was not significant.
Several limitations of the study should be 
noted. First, although the ODYSSEY LONG TERM 
trial followed patients receiving study-drug ther-
apy for a longer period than most other trials of 
PCSK9 inhibitors, the duration of follow-up is 
still relatively short for a treatment for a chronic 
disease, and longer-term studies will be needed. 
Second, the usefulness of the neurocognitive 
findings is limited by the lack of formal neuro-
cognitive testing as part of the study design. 
Third, the number of cardiovascular events was 
relatively small, which limits the robustness of 
these data and the confidence that they are not 
simply a chance finding. ODYSSEY OUTCOMES 
(ClinicalTrials.gov number, NCT01663402) is an 
ongoing trial that is intended to provide an as-
sessment of the cardiovascular benefit of ali-
rocumab in approximately 18,000 patients over a 
period of 5 years.
In conclusion, in the ODYSSEY LONG TERM 
trial, 2341 high-risk patients were randomly as-
signed to either the PCSK9 inhibitor alirocumab 
or placebo. As compared with placebo, alirocumab 
reduced LDL cholesterol levels by 62 percentage 
points at 24 weeks, with a consistent reduction 
over a period of 78 weeks of treatment. In a post 
hoc analysis, there was evidence of a reduction 
in cardiovascular events with alirocumab.
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